The board of directors of Principia Biopharma Inc. appointed John W. Smither as a Class II director of the company, with a term of office expiring at the 2020 annual meeting of stockholders. Concurrently with his appointment to the board, Mr. Smither was also appointed to serve as the chairperson of the audit committee of the board. Mr. Smither currently serves as a board member and chair of the Audit Committee for both Achaogen Inc. and eFFECTOR Therapeutics Inc.